Table 1.
Patient demographic data and baseline characteristics (intention-to-treat population)
| CZP 400 mg (n=89) | |
| Age, mean±SD, years | 30.2±9.9 |
| BMI, mean±SD, kg/m2 | 22.1±3.6 |
| Males, n (%) | 30 (34) |
| CDEIS | |
| Mean±SD | 14.5±5.3 |
| Median | 13.3 |
| IQR | 10.3–16.9 |
| CDAI | |
| Mean±SD | 297±75 |
| Median | 290 |
| IQR | 236–342 |
| CRP, mg/l | |
| Geometric mean (CV) | 19 (1.4) |
| Median | 29 |
| IQR | 9–46 |
| Disease duration, years | |
| Mean±SD | 7.9±7.9 |
| Median | 6.5 |
| Number of resections, n (%) | |
| 0 | 71 (80) |
| 1 | 11 (12) |
| 2 | 5 (6) |
| 3 | 2 (2) |
| Prior anti-TNF therapy, n (%) | 2 (2) |
| At least one concomitant medication potentially influencing CD, % patients | 79 |
| Immunosuppressants | 51 |
| Corticosteroids | 42 |
| 5-Aminosalicylic acid | 22 |
| Antibiotics | 15 |
BMI, body mass index; CD, Chron's disease; CDAI, Crohn's Disease Activity Index; CDEIS, Crohn's Disease Endoscopic Index of Severity; CRP, C reactive protein; CV, coefficient of variation; CZP, certolizumab pegol; TNF, tumour necrosis factor.